×
Endo Common Stock Net 2024-2025 | NDOI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Endo common stock net from 2024 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
Endo Common Stock Net 2024-2025 | NDOI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Endo common stock net from 2024 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$69.6B
Zoetis (ZTS)
$69B
Takeda Pharmaceutical (TAK)
$48.7B
Daiichi Sankyo, - (DSNKY)
$47.9B
BeOne Medicines - (ONC)
$34.4B
Sandoz Group AG (SDZNY)
$26.7B
Summit Therapeutics (SMMT)
$19.3B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.9B
United Therapeutics (UTHR)
$14B
Neurocrine Biosciences (NBIX)
$13.4B
IPSEN (IPSEY)
$11.3B
Orion OYJ (ORINY)
$11.2B
Eisai (ESAIY)
$9.1B
Madrigal Pharmaceuticals (MDGL)
$9B
Corcept Therapeutics (CORT)
$7.5B
Grifols, S.A (GRFS)
$6.9B
Stevanato Group S.p.A (STVN)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.9B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.7B
Procaps Group, S.A (PROCF)
$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.8B
Hypermarcas (HYPMY)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.1B